Diamyd Medical AB (FRA:DMN) Shares Outstanding (EOP): 154.99 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
41 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Shares Outstanding (EOP)?

Diamyd Medical AB FRA:DMN -3.97% 41 Shares Outstanding (EOP) is 154.99 Mil as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Diamyd Medical AB's shares outstanding for the quarter that ended in May. 2026 was 154.99 Mil.

Diamyd Medical AB's quarterly shares outstanding increased from Feb. 2026 (137.50 Mil) to May. 2026 (154.99 Mil). It means Diamyd Medical AB issued new shares from Feb. 2026 to May. 2026 .

Diamyd Medical AB's annual shares outstanding increased from Aug. 2024 (100.19 Mil) to Aug. 2025 (137.50 Mil). It means Diamyd Medical AB issued new shares from Aug. 2024 to Aug. 2025 .


Diamyd Medical AB  (FRA:DMN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Diamyd Medical AB Shares Outstanding (EOP) Related Terms


Diamyd Medical AB Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Shares Outstanding (EOP) Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.65 79.16 86.18 100.19 137.50

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.50 137.50 137.50 137.50 154.99

FRA:DMN vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Shares Outstanding (EOP) falls into.


FRA:DMN
41GF Score
Diamyd Medical AB FRA:DMN
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 154.99 Mil mean?
Diamyd Medical AB (FRA:DMN) has a Shares Outstanding (EOP) of 154.99 Mil as of May. 2026. The total shares a company has outstanding, at period-end. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Shares Outstanding (EOP) too high?
Diamyd Medical AB's current Shares Outstanding (EOP) is 154.99 Mil. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Shares Outstanding (EOP) compare to VRTX and REGN?
Diamyd Medical AB's Shares Outstanding (EOP) of 154.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Shares Outstanding (EOP) is 154.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Shares Outstanding (EOP) is 154.99 Mil. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Shares Outstanding (EOP) is 154.99 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • Shares Outstanding (EOP): 154.99 Mil
  • GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for FRA:DMN

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value